Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carbidopa/levodopa - Amneal Pharmaceuticals

Next Previous
Drug Profile

Carbidopa/levodopa - Amneal Pharmaceuticals

Alternative Names: CREXONT; IPX-203; IPX-203 CD/LD extended-release capsules; IPX203 ER; IPX203 ER CD-LD; IPX203 extended-release capsules

Latest Information Update: 01 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Impax Pharmaceuticals
  • Developer Amneal Pharmaceuticals; Impax Pharmaceuticals; Knight Therapeutics; Zambon Biotech SA
  • Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 01 Jan 2026 Phase-III clinical trials in Parkinson's disease (In adults, In the elderly) in Poland, Spain, Italy (PO) (CTIS2025-521772-57-00)
  • 23 Dec 2025 Zambon submitted IPX203 to the EMA for regulatory approval in June 2025
  • 20 Aug 2025 Zambon Biotech plans a phase III ADIP trial for Parkinson’s disease (In adults, In the elderly) in Italy, Spain, Poland (PO, Capsule) in August 2025 (CTIS2025-521772-57-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top